Human RCTPubMed ID: 39521874·2025

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

Watkins JB, Winthrop KL, Verma AK, et al.

New England Journal of Medicine, 2025 · n = 752

Key finding

Retatrutide superior to tirzepatide: 25.1% vs 21.8% weight loss; p=0.034. Both superior to placebo (2.6%). No significant safety difference between active agents.

Summary

Direct comparison trial randomizing obese adults to retatrutide 15mg, tirzepatide 15mg, or placebo weekly for 72 weeks with weight and metabolic endpoints.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Diabetes Care · 2024 · Human RCT